[1] Han Y,Zeng A, Liao H, et al. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: a systematic review and meta-analysis. Int Immunopharmacol,2017,42:168-175. [2] Zhang J, Wen XY,Gao RP. Hepatitis B virus-related liver cirrhosis complicated with dermatomyositis: A case report. World J Clin Cases, 2019,7(10):1206-1212. [3] Lian JS, Zhang XL, Lu YF, et al. Switching lamivudine with adefovir dipivoxil combination therapy to entecavir monotherapy provides better viral suppression and kidney safety. Int J Med Sci, 2019,16(1):17-22. [4] Zheng H, Liu H, Hao A, et al. Association between serum cystatin C and renal injury in patients with chronic hepatitis B. Medicine (Baltimore), 2020,99(32):e21551. [5] Mori T,Ohsaki Y, Oba-Yabana I, et al. Diuretic usage for protection against end-organ damage in liver cirrhosis and heart failure. Hepatol Res, 2017,47(1):11-22. [6] Kennedy L, Francis H,Invernizzi P, et al. Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis. FASEB J, 2019,(9):10269-10279. [7] Muciño MJ. Mechanisms of kidney dysfunction in the cirrhotic patient: non-hepatorenal acute-on-chronic kidney damage considerations. Ann Hepatol,2020,19(2):145-152. [8] 王贵强,王福生,成军,等.慢性乙型肝炎防治指南(2015年更新版).中华肝脏病杂志,2015,23(12):888-905. [9] Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the international club of ascites. J Hepatol, 2015,62(4):968-974. [10] MacDonald AJ, Nadim MK, Durand F, et al. Acute kidney injury in cirrhosis: implications for liver transplantation. Curr Opin Crit Care, 2019,25(2):171-178. [11] Jiang QQ, Han MF, Ma K, et al. Acute kidney injury in acute-on-chronic liver failure is different from in decompensated cirrhosis. World J Gastroenterol, 2018,24(21):2300-2310. [12] Angeli P, Gines P, Wong F, et al.International Club of Ascites. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut, 2015,64(4):531-537. [13] Deep A, Saxena R, Jose B. Acute kidney injury in children with chronic liver disease. Pediatr Nephrol,2019,34(1):45-59. [14] Kellum JA, Prowle JR. Paradigms of acute kidney injury in the intensive care setting. Nat Rev Nephrol, 2018,14(4):217-230. [15] Wang Y, Bellomo R. Cardiac surgery-associated acute kidney injury: risk factors, pathophysiology and treatment. Nat Rev Nephrol, 2017,13(11):697-711. [16] Mohrer D, Langhan M. Acute kidney injury in pediatric patients: Diagnosis and management in the emergency department. Pediatr Emerg Med Pract, 2017, 14(5):1-24. [17] Ul Abideen Z, Mahmud SN, Salih M, et al. Contrast-induced acute kidney injury in patients with liver cirrhosis: a retrospective analysis. Cureus, 2018,10(5):e2707. [18] Bonavia A, Singbartl K. Kidney injury and electrolyte abnormalities in liver failure. Semin Respir Crit Care Med, 2018,39(5):556-565. [19] Zhong HJ, Sun HH, Xue LF, et al. Differential hepatic features presenting in Wilson disease-associated cirrhosis and hepatitis B-associated cirrhosis. World J Gastroenterol, 2019,25(3):378-387. [20] Stulic M, Culafic D, Obrenovic R, et al. The clinical importance of cystatin C and hepatic artery resistive index in liver cirrhosis. Medicina (Kaunas), 2018,54(3):37. [21] Maiwall R, Pasupuleti SSR, Bihari C, et al. Incidence, risk factors, and outcomes of transition of acute kidney injury to chronic kidney disease in cirrhosis: a prospective cohort study. Hepatology, 2020,71(3):1009-1022. [22] Wu J, Wu Q, Wu M, et al. Serum cystatin C predicts mortality in HBV-related decompensated cirrhosis. Biomed Res Int,2019,2019:7272045. [23] Mauro E, Crespo G, Martinez-GA, et al. Cystatin C and sarcopenia predict acute on chronic liver failure development and mortality in patients on the liver transplant waiting list. Transplantation, 2020,104(7):e188-e198. [24] Tripathi DM, Vilaseca M, Lafoz E, et al. Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension. Gastroenterology, 2018, 155(5):1564-1577. [25] Garbuzenko DV, Arefyev NO, Kazachkov EL. Antiangiogenic therapy for portal hypertension in liver cirrhosis: current progress and perspectives. World J Gastroenterol, 2018,24(33):3738-3748. [26] Clària J, Stauber RE, Coenraad MJ, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology, 2016, 64(4):1249-64. [27] Shalapour S, Lin XJ, Bastian IN, et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature, 2017,551(7680):340-345. [28] Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology, 2017,152(6):1297-1309. [29] Wong GL. Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. Clin Mol Hepatol, 2018, 24(2):108-113. [30] 谯铭铭,王顺,李财昌,等.社区获得性与医院获得性急性肾损伤的临床特点和预后分析.中华肾脏病杂志,2016,32(1):16-23. |